ICHRegulatory IntelligenceGuidance
ICH E8(R1)

General Considerations for Clinical Studies

The foundational ICH efficacy guideline describing the general principles for the design and conduct of clinical studies across a drug development programme. The R1 revision introduces "quality by design" and the concept of identifying factors critical to the quality of a study early, aligning E8 with the risk-proportionate philosophy later embedded in E6(R3).

LAST REVISED
October 2021
PRODUCT AREAS
Clinical
SCOPE & APPLICABILITY

Applies across the clinical development lifecycle for investigational medicinal products in ICH regions; a companion framework to E6 GCP and the E9 statistical principles.

KEY REQUIREMENTS
  • 01Identify factors critical to quality proactively during study design
  • 02Adopt a proportionate, fit-for-purpose approach to study conduct and oversight
  • 03Engage relevant stakeholders, including patients, in study design where appropriate
IMPLEMENTATION TIPS
Run a documented CtQ workshop at protocol concept stage and carry outputs into the monitoring plan
Use E8(R1) as the bridge document when training teams on the E6(R3) quality-by-design shift
REVISION NOTES

R1 revision adopted 6 October 2021, adding quality-by-design and critical-to-quality-factor concepts to the original E8 (1997).

ICH E8(R1): frequently asked questions

Quick answers to common questions about ICH E8(R1).

What is ICH E8(R1)?

ICH E8(R1) — General Considerations for Clinical Studies — is a guidance issued by the International Council for Harmonisation. The foundational ICH efficacy guideline describing the general principles for the design and conduct of clinical studies across a drug development programme. The R1 revision introduces "quality by design" and the concept of identifying factors critical to the quality of a study early, aligning E8 with the risk-proportionate philosophy later embedded in E6(R3).

Who does ICH E8(R1) apply to?

Applies across the clinical development lifecycle for investigational medicinal products in ICH regions; a companion framework to E6 GCP and the E9 statistical principles.

What are the key requirements of ICH E8(R1)?

ICH E8(R1) requires, among other things: Identify factors critical to quality proactively during study design; Adopt a proportionate, fit-for-purpose approach to study conduct and oversight; Engage relevant stakeholders, including patients, in study design where appropriate.

When was ICH E8(R1) last updated?

The current version of ICH E8(R1) dates from October 2021. R1 revision adopted 6 October 2021, adding quality-by-design and critical-to-quality-factor concepts to the original E8 (1997).

RELATED STANDARDS
RELATED FDA RECALLS
where Risk Management & CAPA control fails
See all Risk Management & CAPA recalls →

Live openFDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.

THIS STANDARD IN PRACTICE

Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.

Weekly Briefing

Track the standards that move

When ICH E8(R1) — or any GxP requirement — is revised, recalled against, or clarified by new guidance, the Weekly GxP Briefing surfaces it. Free, one email a week.

Read a past issue →